Detalhe da pesquisa
1.
Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade.
Cell
; 173(3): 624-633.e8, 2018 04 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-29656892
2.
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade.
Cell
; 175(4): 984-997.e24, 2018 11 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30388455
3.
Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses.
Immunity
; 56(6): 1341-1358.e11, 2023 06 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-37315536
4.
A landscape of driver mutations in melanoma.
Cell
; 150(2): 251-63, 2012 Jul 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-22817889
5.
Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
Nature
; 577(7791): 561-565, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31942071
6.
Metabolic heterogeneity confers differences in melanoma metastatic potential.
Nature
; 577(7788): 115-120, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31853067
7.
Author Correction: Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
Nature
; 580(7801): E1, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32238929
8.
Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.
N Engl J Med
; 386(1): 24-34, 2022 01 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34986285
9.
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
N Engl J Med
; 387(17): 1557-1568, 2022 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-36094839
10.
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
Lancet
; 402(10404): 798-808, 2023 09 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-37451295
11.
Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response.
Proc Natl Acad Sci U S A
; 118(43)2021 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34670835
12.
Interdisciplinary management of skin cancer. / Die interdisziplinäre Behandlung von Hautkrebs.
Laryngorhinootologie
; 103(S 01): S100-S124, 2024 May.
Artigo
em Inglês, Alemão
| MEDLINE | ID: mdl-38697144
13.
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.
Lancet Oncol
; 24(11): 1196-1205, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37875144
14.
Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial.
Lancet
; 400(10358): 1117-1129, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36099927
15.
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Lancet
; 399(10336): 1718-1729, 2022 04 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35367007
16.
Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma.
N Engl J Med
; 383(12): 1139-1148, 2020 09 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32877599
17.
The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.
J Transl Med
; 21(1): 753, 2023 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-37880788
18.
B-cell lymphoma-extra large is a promising drug target in Merkel cell carcinoma.
Br J Dermatol
; 189(1): 103-113, 2023 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36991156
19.
Falling off the screening grid-Predictors for postponed utilization of psycho-oncological support in cancer patients and its implications for distress assessment and management.
Psychooncology
; 32(11): 1727-1735, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37789593
20.
Changes in body mass index, weight, and waist-to-hip ratio over five years in HIV-positive individuals in the HIV Heart Aging Study compared to the general population.
Infection
; 51(4): 1081-1091, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-36930373